Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 6/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2212830 | 0.85 | MAOB (0.50) | GRIN2BMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL2212827 | 0.85 | MAOB (0.50) | GRIN2BMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL459537 | 0.85 | GRIN2B (0.65) | GRIN2BMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL20061121 | 0.76 | GRIN2B (0.51) | GRIN2BMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL20061158 | 0.76 | GRIN2B (0.51) | GRIN2BMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL6589968 | 0.73 | CA1 (0.52) | GRIN2BMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL823055 | 0.73 | MTNR1A (0.61) | GRIN2BMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL4606877 | 0.73 | MTNR1A (0.61) | GRIN2BMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL7838746 | 0.73 | MTNR1A (0.61) | GRIN2BMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL29599386 | 0.73 | MTNR1A (0.61) | GRIN2BMTNR1AMTNR1BCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R&D) LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | CNR1, OPRL1, CHRNA10 | GRIN2B 135/4885MTNR1A 42/4885MTNR1B 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.